An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Clinical Trial ID NCT02041533
PubWeight™ 32.45‹?›
🔗 Visit the ClinicalTrials.gov page for NCT02041533
Top papers
| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
Next 100